Application of IL-2 and other cytokines in renal cancer

Bibliography

• JEMAL A, MURRAY T, SASMUELS A et al.: Cancer statistics. CA Cancer J. Clin. (2003) 53:5–26.
   PubMed Web of Science ®Google Scholar
• LINEHAN WM, SHIPLEY WU, PARKINSON DR: Cancer of the kidney and ureter. In: Cancer: Principles and Practice of Oncology. (4th ed.), DeVita Jr VT (Ed.), J. a Lippincott Company, Philadelphia, USA (1993).
   Google Scholar
• MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. EngL J. Med. (1996) 335:865–875.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MAZUMDAR M, BACIK Jet al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J. Clin. OncoL (1999) 17(8):2530–2540. A large retrospective analysis that identified clinical features associated with poor prognosis in metastatic renal cell carcinoma.
   Google Scholar
• MOTZER RJ, BACIK J, MURPHY BA et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. OncoL (2002) 20(1):289–296.
   PubMed Web of Science ®Google Scholar
• •A retrospective analysis that identified clinical features associated with poor prognosis following cytokine (IFN-00 therapy.
   Google Scholar
• GLEAVE ME, ELHILALI M, FRADET Yet al: Canadian Urologic Oncology Group: Interferon gamma-lb compared with placebo in metastatic renal-cell carcinoma. N. Engl J. Med. (1998) 338:1265–1271.
   PubMed Web of Science ®Google Scholar
• OLIVER RT, NETHERSELL AB, BOTTOMLEY JM: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br. J. UroL (1989) 63:128–131.
   PubMedGoogle Scholar
• VOGELZANG NJ, PRIEST ER, BORDEN L: Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J. UroL (1992) 148:1247–1248.
   PubMed Web of Science ®Google Scholar
• MARTEN A, FLIEGER D, RENOTH Set al.: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer ImmunoL Immunother. (2002) 51:637–644.
   Google Scholar
• CHANG AE, LI Q, JIANG Get al.: Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer J Clin. Oncol. (2003) 21:884–890.
   Google Scholar
• FISHMAN M, SEIGNE J: Immunotherapy of metastatic renal cell cancer Cancer Control (2002)9:293–304.
   Web of Science ®Google Scholar
• GITLITZ BJ, BELLDEGRUN AS, FIGLIN RA: Vaccine and gene therapy of renal cell carcinoma Semin. UroL Oncol. (2001) 19:141–147.
   Google Scholar
• L,ESIMPLE T, MOISON A, GUILL,E F et al.: Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor J Immunother. (2000) 23:675–679.
   Google Scholar
• SCHWAAB T, HEANEY JA, SCHNED AR et al.: A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameter& J. Urol. (2000) 163:1322–1327.
   Web of Science ®Google Scholar
• CHILDS R, CHERNOFF A, CONTENTINN et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. (2000) 343:750–758.
   PubMed Web of Science ®Google Scholar
• CHILDS R, SRINIVASAN R: Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumor& Cancer J. Sci. Am. (2002)8:2-1 L
   Google Scholar
• RINI BI, ZIMMERMAN T, STADLER WI\4 et al.: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftrnent, and clinical result& J Clin. Oncol. (2002)20:2017–2024.
   Google Scholar
• ROSENBERG SA, MULE JJ, SPIESS PJ et al.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med. (1985) 161:1169–1188.
   PubMed Web of Science ®Google Scholar
• MULE JJ, YANG JC, LAFRENIERE RL et al.: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. (1987) 139:285–194.
   PubMed Web of Science ®Google Scholar
• NEIDHART JA: Interferon therapy for the treatment of renal cancer. Cancer (1986) 57:1696–1699.
   PubMed Web of Science ®Google Scholar
• MUSS HB: Interferon therapy for renal cell carcinoma. Semin. Oncol. (1987)14:36–42.
   PubMed Web of Science ®Google Scholar
• MUSS HB, COSTANZI JJ, LEAVITT R et al.: Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin. Oncol. (1987) 5:286-29 L
   Google Scholar
• NEGRIER S et al.: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J. Clin. OncoL (2000) 18:4009–4015.
   PubMed Web of Science ®Google Scholar
• FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. EngL J. Med. (2001) 345:1655–1659.
   PubMed Web of Science ®Google Scholar
• •A randomised trial that described a small, but statistically significant, improvement in median survival for patients with metastatic renal cell carcinoma who underwent debulking nephrectomy prior to cytokine (IFN-0&) therapy.
   Google Scholar
• NEIDHART JA, ANDERSON SA, HARRIS JE et al: Vinblastine fails to improve response of renal cancer to interferon alfa-nl : high response rate in patients with pulmonary metastases. J. Clin. OncoL (1991) 9:832–836.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Medical research Council and Collaborators: Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet (1999) 353:14–17.
   PubMed Web of Science ®Google Scholar
• MAZUMDER A, ROSENBERG SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adaptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. (1984) 159:495–507.
   PubMed Web of Science ®Google Scholar
• FISHER RI, COLTMAN CA, DOROSHOW JH et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a Phase II clinical trial. Ann. Intern. Med. (1988) 108:518–521
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MR, MUUL LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. (1987) 316:889–897.
   PubMed Web of Science ®Google Scholar
• •A summary report of the antitumour activity of HD IL-2 and LAK cells in patients with solid tumours.
   Google Scholar
• SUNDERLAND MC, WEISS GR: High dose IL-2 treatment of renal cell carcinoma. In: Therapeutic Applications of Interleulcin-2, Atkins MB, Mier JW (Eds), Marcel Dekker Publishers, New York (1993): 119.
   Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer J. Natl. Cancer Inst. (1993) 85:622–632.
   Google Scholar
• FYFE G, FISHER RI, ROSENBERG SA et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. OncoL (1995) 13:688-696. A summary report of the Phase II trial data of HD IL-2 for patients with metastatic renal cell carcinoma that led to its approval by the FDA.
   Google Scholar
• FISHER RI, ROSENBERG SA, FYFE G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer. J. ScL Am. (2000) 6\(Suppl. 1):555–557.
   Google Scholar
• ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM etal: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Identification of the antigens mediating response. Ann. Surg. (1998) 228:307–319.
   Google Scholar
• DILLMAN RO, OLDHAM RK, TAUER KW et al: Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group Trial. J. Clin. OncoL (1991) 9:1233–1240.
   PubMed Web of Science ®Google Scholar
• WEISS GR, MARGOLIN KA, ARONSON FR: A randomized Phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. OncoL (1992) 10:275–281.
   PubMed Web of Science ®Google Scholar
• GOLD PJ, THOMPSON JA, MARKOWITZ DR et al: Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J. ScL Am. (1997) 3\(Suppl. 1):585-59L
   Google Scholar
• SOSMAN JA, KOHLER PC, HANK J et al: Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J. Natl. Cancer Inst. (1988) 80:60–63.
   PubMed Web of Science ®Google Scholar
• CALIGIURI MA, MURRAY C, ROBERTSON MJ et al: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. (1993) 91:123–132.
   PubMed Web of Science ®Google Scholar
• SLEIJFER DT, JANSSEN RAJ, BUTER Jet al.: Phase H study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on a outpatient basis. J. Clin. Oncol. (1992) 10:1119–1123.
   Google Scholar
• LISSONI P. BORD IN V, VAGHI M et al.:Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Anticancer Res. (202) 22:1061-1064.
   Google Scholar
• LOPEZ HANNINEN E, KIRCHNER H, ATZPODIEN J et al: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risk and benefits in 215 consecutive single institution patients. J. Urol. (1996) 155:19–25.
   PubMed Web of Science ®Google Scholar
• YANG JC, TOPLALIAN SL, PARKINSON D et al: Randomized comparison of high-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. (1994) 12:1572–1576.
   PubMed Web of Science ®Google Scholar
• YANG JC, SHERRY RM, STIENBERG SM et al: A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J. Clin. Oncol. (2003) 21:3127-3132. A large, randomised NCI trial that compared three dose levels of IL-2 and showed significant improvement in response rate, but not overall survival, for HD IL–2.
   Google Scholar
• CAMERON RB, MCINTOSH JK, ROSENBERG SA: Synergistic anti-tumor effects of combinations immunotherapy with recombinant interleukin-2 and a recombinant hybrid alp ha-interferon in the treatment of established murine hepatic metastases. Cancer Res. (1988) 48:5810–5817.
   PubMed Web of Science ®Google Scholar
• IIGO M, SAKURAI M, TAMURA T et al:In vivo anti-tumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. (1988) 48:260–264.
   PubMed Web of Science ®Google Scholar
• CAMERON RB, MCINTOSH JK, ROSENBERG SA: Synergistic anti-tumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alp ha-interferon in the treatment of established murine hepatic metastases. Cancer Res. (1988) 48(20):5810–5817.
   PubMed Web of Science ®Google Scholar
• IIGO M, SAKURAI J, TAMURA T, SADO N, HOSHI A: In vivo anti-tumor activity of multiple injections of recombinant interleukin-2 alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. (1988) 48:260–264.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. (1989)7:1863–1874.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, SPARANO J, FISHER RI et al.: A randomized phase II trial of high dose IL-2 either alone or in combination with interferon alpha 2B in advanced renal cell carcinoma J. Clin. Oncol. (1993) 11:661–670.
   Web of Science ®Google Scholar
• DUTCHER J P, ATKINS M, FISHER R et al.: Interleukin-2-based therapy for metastatic renal cell cancer: the cytokine working group experience, 1989–1997. Cancer J. Sci. Am. (1997) 3\(Suppl. 1):573–578.
   Google Scholar
• SZNOL M, MIER JW, SPARANO J et al.: A phase I study of high-dose interleukin-2 combination with interferon-alfa 2B. J Biol. Response Mod. (1990) 9:529–537.
   PubMedGoogle Scholar
• BERGMAN L, FENCHEL K, WEIDMANN E et al.: Daily alternating administration of high-dose alfa-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell carcinoma Cancer (1993) 72:1733–1742.
   Google Scholar
• SPENCER WF, LINEHAN WM, WALTHER HM et al.: Immunotherapy with interleukin-2 and alpha-interferon in patients with metastic renal cell cancer with in situ primary cancer A pilot study. J Urol. (1992) 147:24–30.
   PubMed Web of Science ®Google Scholar
• BUDD GT, MURHTY S, FINKE Jet al.: Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J. Clin. Oncol. (1992) 10:804–809.
   Google Scholar
• FIGLIN RA, BELL,EGRUN A, MOLDAWER Net al.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma J Clin. Oncol. (1992) 1O:414-42L
   Google Scholar
• LIPTON A, HARVEY H, GIVANT E et al.: Interleukin-2 and interferon-a-2a outpatient therapy for metastatic renal cell carcinoma. J. Immunother. (1993) 13:122–129.
   Web of Science ®Google Scholar
• DILLMAN RO, CHURCH C, OLDHAM RK et al: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group Experience. Cancer (1993) 71:2358–2370.
   Google Scholar
• BELDGRUN A, PIERCE W, KABOO R et al: Interferon-alpha primed tumor-infiltrating lymphocytes with Interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma J. Urol (1993) 150:1384–1390.
   Web of Science ®Google Scholar
• BESANA C, BORRI A, BUCCI E et al: Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous 0C-interferon. Ear. J. Cancer (1994) 9:1292–1298.
   Google Scholar
• NEGRIER S, ESCUDIER B, LASSET C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N. Engl J. Med. (1998) 338:1272-1278. A large, randomised trial that suggested a benefit of the combination of IL-2 and IFN over either agent alone.
   Google Scholar
• ATZPODIEN J, POLIWODA H, KIRCHNER H et al: Alfa-interferon and interleukin-2 in renal cell carcinoma: studies in non-hospitalized patients. Semin. Oncol. (1991) 18(5 Suppl. 7):5108–5112.
   Google Scholar
• PALMER PA, ATZPODIEN J, PHILIP T et al: A comparison of 2 modes of administration of recombinant intereukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alfa in patients with advanced renal cell carcinoma. Cancer Biother. (1993) 8:123–126.
   PubMedGoogle Scholar
• ATZPODIEN J, LOPEZ HANNINEN E, KIRCHNER H et al: Multi-institutional home therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. (1995) 13:497–501.
   PubMed Web of Science ®Google Scholar
• VOGELZANG N, LIPTON A, FIGLIN RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. Clin. Oncol. (1993) 11:1809–1816.
   Web of Science ®Google Scholar
• LUMMEN G, GOEPPEL M, MOLLHOFF S et al: Phase II study of interferon gamma versus interleukin-2 and interferon a2b in metastatic RENAL CELL CARCINOMA. J. Urol. (1996) 155:455–458.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, KICRCHNER H, HANNINEN EL et al: Interleukin-2 in 465 combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer (1993) 29A\(Suppl. 5):S6–S8.
   Google Scholar
• SELLA A, KILBOURN RG, GRAY I et al.: Phase I study of interleukin-2 combined with interferon-alpha and 5- fluorouracil in patients with metastatic renal cell cancer. Cancer Biother. (1994)9:103–111.
   PubMedGoogle Scholar
• HOFMOCKEL G, LANGER W, THEISS M et al.: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil..1 Urol. (1996) 156:18–21.
   Google Scholar
• DUTCHER J P, FISHER RI, WEISS G et al.: Outpatient subcutaneous interleukin-2 plus alpha interferon in metastatic renal cell cancer three year follow-up of the Cytokine Working Group Study. CancerJ. Sci. Am. (1997)3:157–162.
   PubMed Web of Science ®Google Scholar
• CLARK JI, KUZEL TM, LESTINGI TM et al.: A multi-institutional Phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann. Oncol. (202) 13:606–613.
   Google Scholar
• TOURANI JM, PFISTER C, TUBIANA Net al.: Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, Phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. J. Clin. Oncol. (2003) 21:3987–3994.
   Google Scholar
• DUTCHER J P, ATKINS MB, FISHER R et al.: Interleukin-2 based therapy for metastatic renal cell cancer: the Cytokine Working Group Experience, 1989–1997. Can. J. Sci. Am. (1997) 3\(Suppl. 1):573–578.
   Google Scholar
• DUTCHER JP, LOGAN, T, GORDON M et al.: Phase II trial of interleukin-2, interferon-alpha, and 5-fluorouracil in metastatic renal cell cancer: a Cytokine Working Group Study. Clin. Cancer Res. (2000) 6:3442–3450.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT D, FLAHERTY L, CLARK J et al.: A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) 1L2/Interferon (IFN) in patients with metastatic renal cell carcinoma (RENAL CELL CARCINOMA). A Cytokine Working Group Study. Proc. Am. Soc. Clin. Oncol. (2001) 20:172a.
   Google Scholar
• ATKINS MB, MCDERMOTT DF : Results of the Cytokine Working Group Phase III trial of high dose IL-2 vs. low dose IL-2 and IFN therapy in patients with metastatic renal cell carcinoma. Ortho Biotech Oncology, Chemotherapy Foundation Symposium XX Innovative Cancer Therapy for Tomorrow. (2003)72:87–88.
   Google Scholar
• MCDERMOTT D, PARKER R, YOUMANS A et al.: The effect of recent nephrectomy on treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) in patients with metastatic renal cell carcinoma (RENAL CELL CARCINOMA). Proc. Am. Soc. Clin. Oncol. (2003)22:1547.
   Google Scholar
• MARGOLIN KA, RAYNER AA, HAWKINS MJ et al.: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol. (1989) 7:486–498.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:907–913.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. (1993) 85:622–632.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, SPARANO J, FISHER RI et al.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J. Clin. Oncol. (1993) 11:661–670.
   PubMed Web of Science ®Google Scholar
• MIER JW: Pathogenesis of the interelukin-2-induced vascular leak syndrome. In: Therapeutic Applications of Interelukin-2 (1st ed.), Atkins MB (Ed.), Marcel Dekker, Inc., New York, USA (1993).
   Google Scholar
• NUMEROF RP, ARONSON FR, MIER JW: IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J. Immunol. (1988) 141(12):4250–4257.
   PubMed Web of Science ®Google Scholar
• MIER JW, VACHINO G, VANDERMEERJWeta/.:Inductionof circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. (1988) 8:426–436.
   Google Scholar
• LOTZE MT, MATORY YL, ETTINGHAUSEN SE et al.: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol. (1985)135:2865–2875.
   Google Scholar
• HIBBS JB JR, WESTENFELDER C, TA INTO RR et al.: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. (1992) 89:867–877.
   Google Scholar
• MIER JW, VACHINO G, KLEMPNER MS et al.: Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood (1990) 76: 1933-1940.
   Google Scholar
• VETTO JT, PAPA MZ, LOTZE MT et al.:Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J. Clin. Oncol. (1987) 5:496–503.
   PubMed Web of Science ®Google Scholar
• TREHU EG, MIER JW, DUBOIS JS et al.:A phase I trail of interleukin-2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera (TNFR:Fc). J. Clin. Oncol. (1996) 15:1052–1062.
   Google Scholar
• DUBOIS JS, TREHU EG, MIER JW et al.: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol. (1997) 15:1052–1062.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, ATKINS M, SPARANO J et al.: Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin. Cancer Res. (1997)3:565–572.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT D, TREHU EG, DUBOIS Jet al.: Phase I clinical trial of the soluble IL-1 receptor either alone or in combination with high-dose IL-2 in patients with advanced malignancies. Clin. Cancer Res. (1966) 5:1203–1213.
   Google Scholar
• MARGOLIN K, ARONSON FR, SZNOL M et al.: Phase II evaluation of thrice-daily intravenous bolus interleukin-4 in advanced renal cell and malignant melanoma. J. Immunother. (1994) 15:147–153.
   PubMed Web of Science ®Google Scholar
• WEISS GR, MARGOLIN KA, SZNOL M et al.: A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J. Immunother. Emphasis Tumor Immunol. (1995) 18:52–56.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, RAKHIT A, THOMPSON Jet al.: Phase II trial of branched peginterferon-alpha la (40 kDa) for patients with advanced renal cell carcinoma. Ann. Oncol. (2002) 11:1799–1805.
   Google Scholar
• RINI BI, STADLER WM, SPIELBERGER RI, RATAIN MJ, VOGELZANG NJ: Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a Phase II trial. Cancer (1998) 82:1352–1358.
   PubMed Web of Science ®Google Scholar
• WOS E, OLENCKI T, TUASON Let al.: Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer (1996) 77:1149–1153.
   Google Scholar
• VERRA N, JANSEN R, GROENEWEGEN G etal.: Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patient with progressive metastatic renal cell carcinoma. Br. J. Cancer. (2003) 88:1346–1351.
   Google Scholar
• RYAN CVV, VOGELZANG NJ, DUMAS MC, KUZEL T, STADLER WM: Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two Phase II clinical trials. Cancer (2000) 88:1317–1324.
   PubMed Web of Science ®Google Scholar
• SMITH II JVV, DURK RA, BARER AG et al.: Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized Phase I trial in patients with metastatic melanoma and renal cell carcinoma. J. Immunother. (2003) 26:130–138.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, ROBERTSON MJ, GORDON M et al.: Phase I evaluation of intravenous recombinant human interleukin-12 (RHIL-12) in patients with advanced malignancies. Gun. Cancer Res. (1997) 3:409–417.
   Web of Science ®Google Scholar
• MOTZER RJ, RAKHIT A, SCHWARTZ LH et al.: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. (1998) 4:1183–1191.
   PubMed Web of Science ®Google Scholar
• LEONARD J P, SHERMAN ML, FISHER GL et al.: Effects of single-dose IL-12 (IL-12) exposure on IL 12-assoriated toxicity and interferon-y production. Blood (1997) 90:2541–2548.
   PubMed Web of Science ®Google Scholar
• GOLLOB JA, MIER JVV, VEENSTRA K et al.: Phase I trial of twice weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-y induction is associated with clinical response. Clin. Cancer Res. (2000) 6:1678–1692.
   PubMed Web of Science ®Google Scholar
• GOLLOB JA, VEENSTRA KG, PARKER RA et al.: Phase I trial of concurrent twice-weekly rhIL-12 plus low-dose IL-2 in patients with melanoma or renal Cell carcinoma. J. Clin. Oncol. (2003) 21:2564–2573.
   PubMed Web of Science ®Google Scholar
• MESSING EM, MANOLA J, WILDING Get al.: Phase III study of interferon alfa-NL as adjuvant treatment for respectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Tr i al. J. Gin. Oncol. (2003) 21:1214–1222.
   Google Scholar
• PORZSOLT F: Adjuvant therapy of renal cell cancer with interferon alfa-2a. Proc. Am. Soc. Clin. Oncol. (1992) 11:202.
   Google Scholar
• CLARK JI, ATKINS MB, URBA WJ etal.: Adjuvant high-dose bolus interluekin-2 in patients with high-risk renal cell carcinoma - a Cytokine Working Group Phase III Trial. J. Clin. Oncol. (2003) 21:3133–3140.
   Google Scholar
• PANTUCK Al, ZISMAN A, DOREY F et al.: Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer (2003)97:2995–3002.
   Google Scholar
• MICKISCH GH, GARINA, VAN POPPEL H etal.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet (2001) 358:966–970.
   Google Scholar
• MCDERMOTT D, PARKER R, YOUMANS A et al.: The effect of recent nephrectomy on treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-26 (IFN) in patients with metastatic renal cell carcinoma (RENAL CELL CARCINOMA). Proc. Am. Soc. Clin. Oncol. (2003) 22:385.
   Google Scholar
• FIGLIN R, GITLITZ B, FRANKLIN J et al.: Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Am. (1997) 3\(Suppl. 1):592–597.
   Google Scholar
• FALLICK ML, MCDERMOTT DF, LAROCK D et al.: Nephrectomy prior to interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urn!. (1997) 158:1691–1695.
   PubMed Web of Science ®Google Scholar
• ROYAL RE, STEINBERG SM, KROUSE RS et al.: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J. Sci. Am. (1996) 2:91.
   PubMedGoogle Scholar
• ATKINS MB, MIER JVV, PARKINSON DR et al.: Hypothyroidism alter treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. (1988) 318:1557–1563.
   PubMed Web of Science ®Google Scholar
• FUMAGALLI LA, VINKE J, HOFF W et al.: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J. Immunother. (2003) 26:394–402.
   PubMed Web of Science ®Google Scholar
• WEST WH, TAUER KW, YANELLI JR et al.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. (1987) 316:898–905.
   PubMed Web of Science ®Google Scholar
• JANIKJE, SZNOL M, URBA WJ et al.: Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer (1993) 72:2656–2659.
   Google Scholar
• CANGIANO T, LIAO J, NAITOH J etal.: Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J. Clin. Oncol. (1999) 17:523–528.
   Google Scholar
• MOTZER RJ, BACIL J, MARIANI T et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. (2002) 20:2376–2381.
   PubMed Web of Science ®Google Scholar
• UPTON MP, PARKER RA, YOUMANS A, CONNOLLY C, ATKINS MB: Histologic predictors of renal cell carcinoma (RENAL CELL CARCINOMA) response to interleukin-2-based therapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:851.
   Google Scholar
• BUT MH, SELIGSON D, HAN KR etal.: Carbonic anhydrase 1X is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. (2003) 9:802–811.
   Google Scholar
• •Molecular marker (CMX) identified that may predict survival in metastatic renal cell carcinoma.
   Google Scholar
• ATKINS M, MCDERMOTT D, MIER J etal.: High carbonic anhydrase IX expression predicts for renal cancer response to IL-2 therapy. Immunot her. (2003) 26:S39.
   Google Scholar
• DUTCHER J: Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (2002) 16:4–10.
   PubMed Web of Science ®Google Scholar